ArticleFrontiers in microbiology2026
Topical compound acid peeling remodels scalp microbiota and lipid homeostasis in seborrheic dermatitis: a multi-omics study.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current therapeutic options for scalp seborrheic dermatitis (SSD) remain suboptimal, highlighting the demand for more effective and safe treatment strategies. Objective: To investigate the efficacy and underlying mechanisms of a novel 7.5% five-acid compound formulation for the treatment of SSD. Methods: A total of 319 patients diagnosed with SSD at the dermatology outpatient clinic were enrolled. All patients received four sessions of scalp compound acid therapy and were included in efficacy and safety analyses. A subgroup of 30 male participants from the 319-patient cohort underwent scalp sampling before and after treatment for combined microbiomic and lipidomic detection. Meanwhile, 10 matched male SSD patients who did not received compound acid therapy were enrolled as the control group for multi-omics analyses. Results: All 319 SSD patients presented marked relief of scalp erythema, scaling and pruritus after repeated compound acid treatment, with only 6 individuals experiencing temporary mild scalp irritation after the initial treatment. Integrated microbiomic and lipidomic analyses were restricted to a male subcohort (30 treated patients and 10 matched untreated male SSD controls). Within this male subgroup, the relative abundance of the genus Conclusion: The topical scalp compound acid therapy effectively alleviates clinical symptoms in SSD patients and represents a promising novel therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.